Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes.
Adult
Aged
Bile Acids and Salts
Body Weight
Diabetes Mellitus, Type 2
/ drug therapy
Dipeptidyl-Peptidase IV Inhibitors
/ therapeutic use
Gastrointestinal Microbiome
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin
Humans
Hypoglycemic Agents
/ therapeutic use
Liraglutide
/ therapeutic use
Metformin
Middle Aged
RNA, Ribosomal, 16S
Sitagliptin Phosphate
/ therapeutic use
Sulfonylurea Compounds
DPP-4
Dipeptidyl peptidase 4
GLP-1
Glucagon-like peptide 1
Intestinal microbiota
Journal
Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
10
05
2020
revised:
06
08
2020
accepted:
21
12
2020
pubmed:
12
1
2021
medline:
15
12
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
Preclinical data suggest that treatment with either glucagon-like peptide (GLP)-1 receptor agonists or dipeptidyl peptidase (DPP)-4 inhibitors could change the intestinal microbiome and thereby contribute to their beneficial (cardio)metabolic effects. Therefore, our study aimed to investigate the effects of these agents on microbiota composition in adults with type 2 diabetes (T2D). A total of 51 adults with T2D (mean ± SD: age 62.8 ± 6.9 years, BMI 31.8 ± 4.1 kg/m Liraglutide decreased HbA These data suggest that the beneficial effects of liraglutide and sitagliptin on glucose metabolism, body weight and bile acids, when used as add-on therapies to metformin or sulphonylureas, are not linked to changes in the intestinal microbiota (NCT01744236).
Identifiants
pubmed: 33429063
pii: S1262-3636(21)00001-X
doi: 10.1016/j.diabet.2021.101223
pii:
doi:
Substances chimiques
Bile Acids and Salts
0
Dipeptidyl-Peptidase IV Inhibitors
0
Glucagon-Like Peptide-1 Receptor
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
RNA, Ribosomal, 16S
0
Sulfonylurea Compounds
0
Liraglutide
839I73S42A
Metformin
9100L32L2N
Sitagliptin Phosphate
TS63EW8X6F
Banques de données
ClinicalTrials.gov
['NCT01744236']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
101223Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.